Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum

Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00896753

Enrollment

Registered

2009-05-12

Start date

2003-09-30

Completion date

2008-05-31

Last updated

2017-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Metastatic Cancer

Keywords

stage IV colon cancer, liver metastases, lung metastases, recurrent colon cancer

Brief summary

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is using gene expression profiling to evaluate normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum.

Detailed description

OBJECTIVES: * Evaluate gene expression profiles in normal and tumor tissue from patients with colon cancer metastatic to the liver, lungs, or peritoneum. * Establish cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum. * Determine the specific gene expression changes that result in the manifestation of the drug-resistant phenotype for each metastatic site. OUTLINE: This is a pilot study. Tumor and normal tissue collected during surgery are analyzed for gene expression profiling by cDNA microarray. Tissue is also analyzed for thymidylate synthase (TS) gene expression by quantitative PCR and for protein expression by western blot. Gene expression patterns are correlated with TS levels.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of colon cancer metastatic to the liver, lungs, or peritoneum PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum)	day 1
Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum	day 1

Outcome results